Abstract
Heart failure is a leading cause of morbidity and mortality in the United States and worldwide. Despite significant advances in the treatment of heart failure (both pharmacologic and electrical), many patients progress and/or are refractory to these interventions and warrant consideration for advanced therapies, including mechanical circulatory support and/or heart transplantation. The decisions on these approaches are complex and depend on both what is medically appropriate, the patient’s values, and overall goals of care. In particular, due to limited organ availability and significant perioperative risk related to heart transplantation, patients require an extensive medical and psychosocial evaluation by a designated transplant team to stratify the overall risk and the urgency of heart transplantation. Once objective data confirms significant cardiac limitation warranting consideration of cardiac transplantation, evaluation includes ruling out non-cardiac organ dysfunction, other medical comorbidities that could negatively impact on 5-year survival, major immune incompatibility, and cognitive, psychosocial, or behavioral limitations to patient survival. All of these areas are critical to clinical success post-cardiac transplantation. This chapter discusses clinical manifestations and clinical course of heart failure and indications for and medical evaluation for heart transplantation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Mozaffarian D, et al. Heart disease and stroke statistics-2016 update a report from the American Heart Association. Circulation. 2016;133:e38–360.
Ambrosy AP, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33.
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368–76.
Heidenreich PA, et al. Forecasting the impact of heart failure in the United States a policy statement from the american heart association. Circ Heart Fail. 2013;6:606–19.
Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.
Mehra MR, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35:1–23.
Mehra MR, et al. Guidelines for listing candidates for heart transplant. JAMA Cardiol. 2016;34:1244–54.
Jessup M, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and Management of Heart Failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.
Gheorghiade M, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–68.
Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–2200m.
Chaudhry S-P, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12:323–33.
Friedrich EB, Böhm M. Management of end stage heart failure. Heart. 2007;93:626–31.
Yusen RD, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation report – 2016; Focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1170–84.
Mancini DM, Schulze PC. Heart transplant allocation: in desperate need of revision. J Am Coll Cardiol. 2014;63:1179–81.
Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19:1–8.
Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173–83.
Doumouras BS, et al. Outcomes in adult congenital heart disease patients undergoing heart transplantation: a systematic review and meta-analysis. J Heart Lung Transplant. 2016;35:1337–47.
Levy WC, et al. The seattle heart failure model. Circulation. 2006;113:1424 LP–1433.
Aaronson KD, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660 LP–2667.
Eckman PM, Hanna M, Taylor DO, Starling RC, Gonzalez-Stawinski GV. Management of the sensitized adult heart transplant candidate. Clin Transpl. 2010;24:726–34.
Politi P, et al. Ten years of ‘extended’ life: quality of life among heart transplantation survivors. Transp J. 2004;78:257–63.
Yusen RD, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report – 2015; Focus theme: early graft failure. J Heart Lung Transplant. 2015;34:1264–77.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Rhee, J., Vagelos, R. (2019). End-Stage Heart Disease and Indications for Heart Transplantation. In: Sher, Y., Maldonado, J. (eds) Psychosocial Care of End-Stage Organ Disease and Transplant Patients. Springer, Cham. https://doi.org/10.1007/978-3-319-94914-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-94914-7_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94913-0
Online ISBN: 978-3-319-94914-7
eBook Packages: MedicineMedicine (R0)